Literature DB >> 7945180

[Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA].

H Mahnel1, A Mayr.   

Abstract

Immunizations against orthopox virus infections require a replicating, but safe vaccinia virus. The strain MVA is well suited concerning this matter. Human beings and animals can be vaccinated without any risk. The virus propagated in cell culture is non-virulent and lost its contagiosity. Multiplication in vaccinated men and animals is limited and excretion does not happen. As known for other attenuated virus strains, there must be a minimal effective virus concentration in the vaccine, which is 10(7.5) TCID50 per ml for MVA. To achieve a solid basic immunity which endures for a minimal of one year, two parenteral applications of MVA at intervals of at least 3 weeks are necessary.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7945180

Source DB:  PubMed          Journal:  Berl Munch Tierarztl Wochenschr        ISSN： 0005-9366            Impact factor:   0.328


  15 in total

1.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.

Authors:  Koen K A Van Rompay; Jennifer L Greenier; Kelly Stefano Cole; Patricia Earl; Bernard Moss; Jonathan D Steckbeck; Bapi Pahar; Tracy Rourke; Ronald C Montelaro; Don R Canfield; Ross P Tarara; Christopher Miller; Michael B McChesney; Marta L Marthas
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.

Authors:  M W Carroll; W W Overwijk; R S Chamberlain; S A Rosenberg; B Moss; N P Restifo
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

4.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

5.  Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Raquel Conde; Alberto Pascual-Montano; Keith Harshman; Mariano Esteban
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

Authors:  Rama Rao Amara; Francois Villinger; Silvija I Staprans; John D Altman; David C Montefiori; Natalia L Kozyr; Yan Xu; Linda S Wyatt; Patricia L Earl; James G Herndon; Harold M McClure; Bernard Moss; Harriet L Robinson
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.

Authors:  M Magdalena Gherardi; José Luis Nájera; Eva Pérez-Jiménez; Susana Guerra; Adolfo García-Sastre; Mariano Esteban
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.

Authors:  G S Taylor; T A Haigh; N H Gudgeon; R J Phelps; S P Lee; N M Steven; A B Rickinson
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation.

Authors:  Laura E McCoy; Aodhnait S Fahy; Ron A-J Chen; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2010-05-05       Impact factor: 3.891

10.  Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.

Authors:  Robert J Amato; Mika Stepankiw
Journal:  Clin Med Insights Oncol       Date:  2012-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.